0 Table of Contents |
1 IDEA4RC FHIR IG - Home Page |
2 IDEA4RC Model Overview |
3 IDEA4RC Detailed ERD Model |
4 IDEA4RC Logical Models |
5 Useful Downloads |
6 Condition-secondaryCancer-eu-i4rc Relationships |
7 Encounter-eu-i4rc Relationships |
8 Condition-primaryCancer-eu-i4rc Relationships |
9 sarcoma-cancer-stage-group Relationships |
10 hn-cancer-stage-group Relationships |
11 episodeOfCare-eu-i4rc Relationships |
12 MedicationAdministration-eu-i4rc Relationships |
13 Subject Relationships |
14 PatientFollowUp Relationships |
15 EpisodeEvent Relationships |
16 OtherTreatment Relationships |
17 HospitalPatientRecords Relationships |
18 HnStage Relationships |
19 CancerEpisode Relationships |
20 AdverseEvent Relationships |
21 GeneticTestExpression Relationships |
22 SarcomaStage Relationships |
23 Surgery Relationships |
24 Radiotherapy Relationships |
25 Artifacts Summary |
25.1 Adverse Event |
25.2 Cancer Episode |
25.3 Episode Event |
25.4 Genetic Test Expression |
25.5 Head and Neck Stage |
25.6 Hospital Patient Records |
25.7 Other Local Treatment |
25.8 Pathological Report Info |
25.9 Patient |
25.10 Patient Follow-Up |
25.11 Radiotherapy |
25.12 Sarcoma Stage |
25.13 Surgery |
25.14 Systemic Treatment |
25.15 Treatment Response |
25.16 Cancer Episode Model to this guide Map |
25.17 Episode Event Model to this guide Map |
25.18 Genetic Test Expression Model to this guide Map |
25.19 Genetic Test to this guide Map |
25.20 Head and Neck Stage Model to this guide Map |
25.21 Hospital Patient Records Model to this guide Map |
25.22 Patient (Subject) Model to this guide Map |
25.23 Patient Follow up Model to this guide Map |
25.24 Radiotherapy Model to this guide Map |
25.25 Sarcoma Stage Model to this guide Map |
25.26 Surgery Model to this guide Map |
25.27 Observation: Alcohol use |
25.28 Observation: Cancer Treatment |
25.29 Observation: Charlson Comorbidity Index |
25.30 Observation: Comorbidities |
25.31 Observation: ECOG Performance Status |
25.32 Observation: Karnofsky Performance Status |
25.33 Observation: Occurrence of the other cancer |
25.34 Observation: Tobacco use |
25.35 Patient: IDEA4RC |
25.36 Condition: Metastatic Cancer |
25.37 Condition: Primary Cancer |
25.38 Observation: Diagnosis details |
25.39 Observation: Head Neck Cancer Stage Group |
25.40 Observation: Localized Category (Stage, Sarcoma) |
25.41 Observation: LocoRegional Category (Stage, Sarcoma) |
25.42 Observation: Radiological Extra-nodal extension (rENE) |
25.43 Observation: Sarcoma Cancer Stage Group |
25.44 Observation: TNM Distant Metastases Category |
25.45 Observation: TNM Primary Tumor Category |
25.46 Observation: TNM Regional Nodes Category |
25.47 Encounter: IDEA4RC |
25.48 Observation: date of the last contact |
25.49 Observation: Status at the Last Follow Up |
25.50 Procedure: Surgery |
25.51 Procedure: Radiotherapy |
25.52 MedicationAdministration: Chemotherapy |
25.53 EpisodeOfCare: IDEA4RC |
25.54 AdverseEvent: IDEA4RC |
25.55 Bundle: IDEA4RC |
25.56 Observation: test results |
25.57 Observation: Yes / No assertions |
25.58 Procedure: Other Treatment |
25.59 Body Location Qualifier |
25.60 Condition related to resource |
25.61 Laterality Qualifier |
25.62 Performed Timing |
25.63 Previous Status |
25.64 Race Extension |
25.65 Radiotherapy Dose Delivered To Volume Extension |
25.66 Radiotherapy Energy or Isotope |
25.67 Radiotherapy Modality And Technique Extension |
25.68 Radiotherapy Modality Extension |
25.69 Radiotherapy Number of Sessions Extension |
25.70 Radiotherapy Technique Extension |
25.71 Relapse Type |
25.72 Same custodian flag |
25.73 Affected Organs (surgery) |
25.74 Alcohol Usage Status: Athena |
25.75 Alcohol Usage Status: SNOMED CT |
25.76 Antineoplastic and immunostimulating agents |
25.77 Beam Quality |
25.78 Body site qualifier |
25.79 Calculated|Estimated |
25.80 Cancer Chondro Osseous Tumours: Athena |
25.81 Cancer diagnosis: Athena |
25.82 Cancer Endometrial stromal and related Tumors: Athena |
25.83 Cancer Event Type: Athena |
25.84 Cancer Histology Adenocarcinoma: Athena |
25.85 Cancer Histology Neuroendocrine: Athena |
25.86 Cancer Histology Odontogenic Carcinoma: Athena |
25.87 Cancer Histology SNUC: Athena |
25.88 Cancer Histology Squamous: Athena |
25.89 Cancer Histology Subgroup Adipocytic Tumours: Athena |
25.90 Cancer Histology Subgroup Fmt Tumours: Athena |
25.91 Cancer Histology Subgroup So called Fibrohistiocytic Tumours: Athena |
25.92 Cancer Miscellanious mesenchimal tumors: Athena |
25.93 Cancer Mixed epithelial and mesenchymal tumours: Athena |
25.94 Cancer Pericytic Perivascular Tumours: Athena |
25.95 Cancer Peripheral Nerve Sheath Tumors: Athena |
25.96 Cancer Skeletal Muscle Tumours: Athena |
25.97 Cancer Smooth Muscle Tumours: Athena |
25.98 Cancer Stage Grading: Athena |
25.99 Cancer Stage Group Value: Athena |
25.100 Cancer Stage Group: Athena |
25.101 Cancer Tumors Of Uncertain Differentiation: Athena |
25.102 Cancer undif. small round cell sarcomas of bone and soft tissue: Athena |
25.103 Cancer Vascular Tumours: Athena |
25.104 Chemotherapy cumulative dose units |
25.105 Comorbidities: Athena |
25.106 Comorbidities: SNOMED |
25.107 Country: athena |
25.108 Current Smoking Status: Athena |
25.109 ECOG Performance Status |
25.110 Event Type |
25.111 Extranodal Extension |
25.112 Gender: Athena |
25.113 Genetic Tests performed (Yes/no/Unk) |
25.114 Genito urinary subsite: Athena |
25.115 Hypopharynx subsite: Athena |
25.116 Hypopharynx subsite: Snomed CT |
25.117 Intra abdominal subsite: Athena |
25.118 Intra thoracic subsite : Athena |
25.119 Larynx subsite: Athena |
25.120 Larynx subsite: Snomed CT |
25.121 Lip subsite: Athena |
25.122 Lip subsite: Snomed CT |
25.123 Margins After Surgery |
25.124 Metastatis: Athena |
25.125 Nasal cavity and paranasal sinuses subsite: Athena |
25.126 Nasal cavity and paranasal sinuses subsite: Snomed CT |
25.127 Nasopharynx subsite: Athena |
25.128 Nasopharynx subsite: Snomed CT |
25.129 Not Performed|Unknown |
25.130 Observation Codes for Distant Metastases Category |
25.131 Observation Codes for Primary Tumor Category |
25.132 Observation Codes for Regional Node Category |
25.133 Occurrence of other cancer |
25.134 Oral cavity subsite: Athena |
25.135 Oral cavity subsite: Snomed CT |
25.136 Oropharynx subsite: Athena |
25.137 Oropharynx subsite: Snomed CT |
25.138 Pathological M |
25.139 Pathological N |
25.140 Pathological T |
25.141 Positive-Negative-No Test: Athena |
25.142 Race |
25.143 Radiotherapy Device Type |
25.144 Reason For End Of Treatment |
25.145 Sarcoma Staging: localized disease |
25.146 Sarcoma Staging: loco-regional category |
25.147 Setting Radiotherapy |
25.148 Simple measures |
25.149 Site of metastasis |
25.150 Site rare (IDEA4RC) |
25.151 Smoking Status: LOINC |
25.152 Status at the Last Follow Up |
25.153 Subsites: Athena |
25.154 Subsites: SNOMED CT |
25.155 Surgery Complication |
25.156 Surgery Intention |
25.157 Surgery Outcome |
25.158 Surgical Complications |
25.159 Surgical Procedure Category |
25.160 Surgical Procedure Type |
25.161 TNM Distant Metastases Category Value Set |
25.162 TNM Primary Tumor Category Value Set |
25.163 TNM Regional Nodes Category Value Set |
25.164 Tobacco Product |
25.165 Treatment completed as planned |
25.166 Treatment Response |
25.167 Treatment Setting |
25.168 Treatment Technique |
25.169 Trunk wall subsite: Athena |
25.170 Type of Biopsy |
25.171 Type of Diagnosis |
25.172 Type of surgical approach |
25.173 Type of Systemic Treatment |
25.174 Type of Treatment |
25.175 Types of Yes/No observations |
25.176 Upper and Lower limbs subsite: Athena |
25.177 Yes-No-Unk: Athena |
25.178 IDEA4RC Code System |
25.179 Other Treatment to this guide Map |
25.180 Radiotherapy Model to this guide Map |
25.181 Actor: Head and Neck |
25.182 Actor: Sarcoma |
25.183 Condition: Grade 2 tumor with several body sites and evidences |
25.184 Condition: Metastasis bone and pleura |
25.185 Condition: NOT CLEAR WHAT IT REPRESENTS..TO BE DISCUSSED |
25.186 Condition: Stable Disease |
25.187 encounter-id-14 |
25.188 EpisodeOfCare |
25.189 GOFSH-GENERATED-id-28 |
25.190 GOFSH-GENERATED-id-30 |
25.191 GOFSH-GENERATED-id-36 |
25.192 Observation: Alcohol use |
25.193 Observation: BMI |
25.194 Observation: C reactive protein Positive |
25.195 Observation: Charlson Comorbidity Index |
25.196 Observation: comorbidity |
25.197 Observation: date of the last contact |
25.198 Observation: Diagnosis |
25.199 Observation: Dimension of Tumor |
25.200 Observation: Distant metastases clinical M1 |
25.201 Observation: Distant metastases pathology M1 |
25.202 Observation: ECOG Performance Status score |
25.203 Observation: Epstein Barr virus DNA Negative |
25.204 Observation: gene Mutation Analysis Performed yes |
25.205 Observation: Human papilloma virus Negative |
25.206 Observation: immunohiostochemestry analysis performed |
25.207 Observation: Karnofsky Performance Status score |
25.208 Observation: Number of mitoses per HPF |
25.209 Observation: Occurrence of other Cancer: Hamartoma |
25.210 Observation: Primary tumor clinical T0 |
25.211 Observation: Primary tumor pathological T0 |
25.212 Observation: Radiological Extra-nodal extension |
25.213 Observation: Regional lymph nodes Clinical N1 |
25.214 Observation: Regional lymph nodes pathology N3b |
25.215 Observation: Surgery treatment occurred |
25.216 Observation: TNM clinical stage grouping |
25.217 Observation: TNM pathology stage grouping |
25.218 Observation: Tobacco use panel |
25.219 Patient: race extension |
25.220 Procedure: Isolated limb perfusion |